Jounce Therapeutics (JNCE) is Initiated by Wells Fargo to “Outperform”

Jounce Therapeutics (JNCE) was Initiated by Wells Fargo to “Outperform”. Wells Fargo advised their Clients and Investors in a research report released on Feb 21, 2017.

Based on several research reports , JP Morgan Initiated Jounce Therapeutics on Feb 21, 2017 to “Overweight”, Price Target of the shares are set at $28.

Jounce Therapeutics

Add Comment